Pegfilgrastim-induced leukocytosis and hyperleukocytosis

Abstract

Objective To report a case of leukocytosis (LCT) and hyperleukocytosis (HLCT) episodes post Pegfilgrastim (Neulasta) administration.

Case Summary A 74-year-old female presented with several episodes of LCT and HLCT following administration of Pegfilgrastim while undergoing adjunct dose dependent chemotherapy for adenocarcinoma of the gallbladder. The patient had completed cycle 6, day 8 of chemotherapy and subsequently received Neulasta 48 hours later. Two days later, she presented to the ER with white blood cell (WBC) count of 110K. Prior to Neulasta administration, her WBC counts were within normal range and after each episode of leukocytosis, the patient’s WBC count trended downward. Upon consultation, hematology considered Pegfilgrastim as a likely cause for this patient’s WBC cycling and HLCT.

Discussion Pegfilgrastim-induced HLCT occurs in less than 1% of patient cases. Dose-dependent chemotherapy combined with Pegfilgrastim treatment is an optimal treatment option to reduce the length of chemotherapy schedules and risk of febrile neutropenia. Following the dosing of Pegfilgrastim, the drug clearance is mediated by neutrophil receptors which results in a reduction of ANC values.

Conclusions Further studies are needed to determine the optimum timing and dosage of Pegfilgrastim to offer maximum myeloprotective benefit while also minimizing the risks of adverse events such as leukocytosis and hyperleukocytosis experienced by our patient.

Keywords

Leukocytosis / Hyperleukocytosis / Neulasta / Pegfilgrastim / ANA / G-CSF

References

[1] Inc A. Neulasta Highlights of Prescribing Information. These highlights do not include all the information needed to use NEULASTA safely and effectively. U.S. Food and Drug Administration 2015.

[2] Lambertini M, Bruzzi P, Poggio F, et al. Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracyclineand taxane-based chemotherapy in breast cancer patients: a singlecenter experience within the GIM2 randomized phase III trial. Support Care Cancer. 2016; 24(3): 1285-94. PMid:26306520. https://doi.org/10.1007/s00520-015-2907-2

[3] Takuwa H, Tsuji W, Goto T, et al. Pegfilgrastim-induced fatigue and leukocytosis improved following dose reduction in a young patient with breast cancer: A case report. Mol Clin Oncol. 2019 ; 11(4): 371-5.

[4] Li L, Ma S, Wu M, et al. The prophylactic effects of long-acting granulocyte colony-stimulating factor for febrile neutropenia in newly diagnosed patients with epithelial ovarian cancer: a randomised controlled study. BMJ Support Palliat Care. 2019; 9(4): 373-80. PMid:31467066. https://doi.org/10.1136/bmjspcare-2019-001862

[5] Chavda R, Herrington JD. Pegfilgrastim-induced hyperleukocytosis leading to hospitalization of a patient with breast cancer. Proc (Bayl Univ Med Cent). 322019. p. 261-2. PMid:31191148. https://doi.org/10.1080/08998280.2018.1547873

[6] Wessels H, Lehnick D, Höfler J, et al. Pharmacodynamics, safety, and immunogenicity of Pelmeg( R ), a pegfilgrastim biosimilar in healthy subjects. Pharmacol Res Perspect. 2019; 7(5): e00507. PMid:31417681. https://doi.org/10.1002/prp2.507

[7] Nancy Berliner. Leukocytosis and Leukopenia,. In: Editor(s): Lee Goldman AIS, editor. ISBN 9781437716047, 24th Edition ed: Willey; 2012. p. 170.

[8] Ohkura Y, Ueno M, Udagawa H. Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5- fluorouracil. World J Surg Oncol. 2019; 17(1): 125. PMid:31315622. https://doi.org/10.1186/s12957-019-1665-x